Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Filings indexed 1,070 across all filing types
Latest filing 2024-12-05 Director's Dealing
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-12-05 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-12-05 English
8-K
Regulatory Filings
2024-11-13 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-13 English
SELLAS LIFE SCIENCES GROUP, INC.
Major Shareholding Notification
2024-11-08 English
FORM 8-K
Regulatory Filings
2024-10-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.